anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Disclosed is an oxidative dye for oxidative color change of keratinic fibers, in particular human hair, comprising: at least one alkalising agent; at least one oxidative dye precursor of the developer type; at least one oxidative dye precursor of the coupler type; at least one extract of Quassia amara and, based on the weight of the oxidative dye, from about 0 to less than about 0.1 wt % peroxide compounds. Most preferably, the at least one extract of Quassia amara amounts to 0.15 to 0.5 wt.% based on the total composition. Preferably, the extract is obtained from the bark-free wood of the plant. Preferably, the oxidative dye contains at least one cosmetic oil (e.g. natural and synthetic hydrocarbons (e.g. paraffin oils, isoparaffins etc.)). Preferably, the composition further comprises a surfactant.
Clindamycin/benzoyl peroxide (Duac® Topical Gel)applied to entire face in the morning. Adapalene (Differin® 0.3% Gel) applied to entire face in the evening. Daily treatment for 12 weeks.
PURPOSE: To obtain an agent which contains, as an active ingredient, a non-N- methyl-D-aspartate(NMDA)-antagonist and is useful for treating an abstinence symptom due to drug abuse and inhibiting drug dependency. CONSTITUTION: This agent contains, as an active ingredient a non-NMDA- antagonist or its salt, which shows an excitatory amino acid action. A combination of the agent and an NMDA-antagonist can be prepared as another agent. The non-NMDA-antagonist is a quisqualate antagonist having a selective or unselective action on an AMPA-receptor. The agent is useful for treating an abstinence symptom caused by taking any of sedative substances, opium agents, hallucinogenic agents, other narcotic agents or alcohol. The daily dose of the agent is 0.001 to 0.0034 mg.
Nucleotide-binding domain leucine-rich repeat and pyrin domain-containing protein 3 (NLRP3) is a downstream protein from the pattern recognition receptor family that forms the NLRP3 inflammasome. The NLRP3 inflammasome releases caspase-1, IL-1β, and IL-18, contributing to inflammatory responses associated with diabetes mellitus, arthritis, and ischemia-reperfusion injury. Recent studies suggest that specific saponin monomers and extracts from traditional Chinese medicines can inhibit inflammatory responses and related pathways, including the production of inflammatory factors. MCC950 is one of the most influential and specific NLRP3 inhibitors. Comparative molecular docking studies have identified 22 of the 37 saponin components as more robust binders to NLRP3 than MCC950. Dioscin, polyphyllin H, and saikosaponin-a have the highest binding affinities and potential NLRP3 inhibitors, offering a theoretical basis for developing novel anti-inflammatory therapies.
Repeated back extension exercise as described by McKenzie in prone position was performed of three sets of ten repetitions with one minute rest between the sets. The patient was asked to reach the maximum extension possible in all attempts and maintain this position for one second. The intervention was done 3 times per week for 6 weeks.
Subjects will have one treatment session at week 0 and two live assessment visits at weeks 2 and 12. Approximately 20 units of prabotulinumtoxinA-xvfs will be injected into the left side of the subject's glabellar lines and forehead region, and a placebo saline treatment will be injected into the right side of the subject's glabellar lines and forehead region.
RTR volunteers will contact the participants in this group by telephone once a week, providing support and information integral to RTR. The volunteers will also review the educational materials sent to all participants receiving RTR services. This will allow the volunteers to build a relationship with the participants over 12 weeks and ensure that these participants receive a minimal intervention, reducing the risk of attrition at the 12-week assessment.
The invention relates to a bifidobacterium BB2 that is separated from the alimentary canal of healthy broilers and can generate bacteriocin or bacteriostatic substances, and the collection number is CGMCC No. 3200. The strain has the advantages of strong stress resistance, rapid growth, high acidness of fermentation liquor, large biomass, bacteriostatic or antibacterial activity and the like. The invention also relates to a large-scale fermentative culture method of the strain, and bactericide with viable count of 12-15 billion/g can be obtained by centrifuging the fermentation liquor to recover bacterial sludge and adding protective agent after freeze drying. The bifidobacterium subspecies BB2 preparation can partially substitute for antibiotics, eliminate drug residues, improve the quality of animal products, animal productivity and immunity or disease resistance, reduce the mortality and elimination rate of animals and diarrhoea rate, and also purify the environment of animal houses. The strain, the method and the application have high social, economic and ecological benefits.
BACKGROUND: Renal fibrosis significantly contributes to the progressive loss of kidney function in chronic kidney disease (CKD), with alternatively activated M2 macrophages playing a crucial role in this progression. The serum succinate level is consistently elevated in individuals with diabetes and obesity, both of which are critical factors contributing to CKD. However, it remains unclear whether elevated succinate levels can mediate M2 polarization of macrophages and contribute to renal interstitial fibrosis.
METHODS: Male C57/BL6 mice were administered water supplemented with 4% succinate for 12 weeks to assess its impact on renal interstitial fibrosis. Additionally, the significance of macrophages was confirmed in vivo by using clodronate liposomes to deplete them. Furthermore, we employed RAW 264.7 and NRK-49F cells to investigate the underlying molecular mechanisms.
RESULTS: Succinate caused renal interstitial macrophage infiltration, activation of profibrotic M2 phenotype, upregulation of profibrotic factors, and interstitial fibrosis. Treatment of clodronate liposomes markedly depleted macrophages and prevented the succinate-induced increase in profibrotic factors and fibrosis. Mechanically, succinate promoted CTGF transcription via triggering SUCNR1-p-Akt/p-GSK3β/β-catenin signaling, which was inhibited by SUCNR1 siRNA. The knockdown of succinate receptor (SUCNR1) or pretreatment of anti-CTGF(connective tissue growth factor) antibody suppressed the stimulating effects of succinate on RAW 264.7 and NRK-49F cells.
CONCLUSIONS: The causative effects of succinate on renal interstitial fibrosis were mediated by the activation of profibrotic M2 macrophages. Succinate-SUCNR1 played a role in activating p-Akt/p-GSK3β/β-catenin, CTGF expression, and facilitating crosstalk between macrophages and fibroblasts. Our findings suggest a promising strategy to prevent the progression of metabolic CKD by promoting the excretion of succinate in urine and/or using selective antagonists for SUCNR1.
The invention discloses antiphlogistic antibacterial paint for treating eczema dermatitis, and a detection method thereof. The paint consists of adrenal cortex hormone, broad-spectrum antibiotics, antiphlogistic analgesics and drug transdermal absorption accelerator. The preparation has antiphlogistic, analgesic, antipruritic, antibacterial, antifungal and anti-allergic efficacies, and has unique effects of treating various skin inflammations, itching, allergies and bacterial/fungal infections. The paint can be used for eczema (sub-acute/chronic phase), dermatitis (seborrheic dermatitis, neurodermatitis, contact dermatitis, allergic dermatitis, insect bite dermatitis and the like), prurigo, pruritus, drug eruption, pompholyx, manus and tinea pedis, psoriasis, finger-palm keratosis, vitiligo, pityriasis rosea and the like. While studying antiphlogistic antibacterial paint, the invention also establishes a simple reliable medicine detection method for the antiphlogistic antibacterial paint. The method adopts high performance liquid chromatography and can simultaneously and accurately detect the content of three main medicaments under detection wavelength of 254 nm and other conditions.
According to an aspect, influence filtering in a graphical model includes accessing the graphical model in a data store. The graphical model includes a plurality of nodes connected by edges having edge strengths representing a degree of relation between the nodes. A target relation strength for a pair of nodes in the graphical model is received. An edge strength of an edge in a direct path between the pair of nodes is determined by traversing, in the graphical model, one or more paths other than the direct path between the pair of nodes. The determining also includes estimating a cumulative strength of the traversed paths, and calculating the edge strength for the edge in the direct path based on the cumulative strength of the traversed paths and the target relation strength. The calculated edge strength is assigned to the edge in the direct path between the two nodes.
BACKGROUND: At present, the only opportunity to omit axillary staging is with Choosing Wisely criteria for women ages >70 y with cT1 2N0 estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast cancer. However, many women are diagnosed when pathologic node status-negative, raising the question of additional opportunities to omit sentinel lymph node biopsy. We sought to investigate the association between MammaPrint, a genomic test that estimates estrogen receptor-positive breast cancer recurrence risk, and pathologic node status, with the aim that low-risk MammaPrint could be considered for omission of sentinel lymph node biopsy if associated with pathologic node status-negative.
METHODS: A single-institution database was queried for all women with cT1 2N0 estrogen receptor-positive/human epidermal growth factor receptor 2-negative invasive breast cancer with breast surgery as their first treatment and MammaPrint performed from 2020 to 2021. Patient and tumor factors, including MammaPrint score, were compared with axillary node status for correlation.
RESULTS: A total of 668 women met inclusion criteria, with a median age of 66 y. MammaPrint was low-risk luminal A in 481 (72%) and high-risk luminal B in 187 (28%). At the time of breast surgery, 588 (88%) had sentinel lymph node biopsy, 27 (4%) had axillary lymph node dissection, and 53 (7.9%) had no axillary staging. Most women in both the pathologic node status-negative and pathologic node status-positive cohorts had low-risk MammaPrint (355 [73.3%] pathologic node status-negative vs 91 [69.5%] pathologic node status-positive), and women with low-risk MammaPrint did not have a significantly lower risk of pathologic node status-positive (P = .377).
CONCLUSION: Low-risk MammaPrint does not predict lower risk of pathologic node status-positive breast cancer. Based on our results, genomic testing does not appear to provide additional personalization for the ability to omit sentinel lymph node biopsy for patients outside of the Choosing Wisely guidelines.
In a placebo-controlled clinical trial of patients with RA, no difference was detected in anti-pneumococcal antibody response between adalimumab and placebo treatment groups when the pneumococcal polysaccharide vaccine and influenza vaccine were administered concurrently with adalimumab. Similar proportions of patients developed protective levels of anti-influenza antibodies between adalimumab and placebo treatment groups; however, titers in aggregate to influenza antigens were moderately lower in patients receiving adalimumab. The clinical significance of this is unknown. Patients on ABRILADA may receive concurrent vaccinations, except for live vaccines. No data are available on the secondary transmission of infection by live vaccines in patients receiving adalimumab products.

It is recommended that pediatric patients, if possible, be brought up to date with all immunizations in agreement with current immunization guidelines prior to initiating ABRILADA therapy. Patients on ABRILADA may receive concurrent vaccinations, except for live vaccines.

The safety of administering live or live-attenuated vaccines in infants exposed to adalimumab products in utero is unknown. Risks and benefits should be considered prior to vaccinating (live or live-attenuated) exposed infants [see Use in Specific Populations (8.1, 8.4)].
AUGMENTIN XR Extended Release Tablets are indicated for the treatment of patients with community-acquired pneumonia or acute bacterial sinusitis due to confirmed, or suspected β-lactamase−producing pathogens (i.e., H. influenzae, M. catarrhalis, H. parainfluenzae, K. pneumoniae, or methicillin-susceptible S. aureus) and S. pneumoniae with reduced susceptibility to penicillin (i.e., penicillin MICs = 2 mcg/mL). AUGMENTIN XR is not indicated for the treatment of infections due to S. pneumoniae with penicillin MICs ≥ 4 mcg/mL. Data are limited with regard to infections due to S. pneumoniaewith penicillin MICs ≥ 4 mcg/mL (see CLINICAL STUDIES).

Of the common epidemiological risk factors for patients with resistant pneumococcal infections, only age > 65 years was studied. Patients with other common risk factors for resistant pneumococcal infections (e.g., alcoholism, immune-suppressive illness, and presence of multiple co-morbid conditions) were not studied.

In patients with community-acquired pneumonia in whom penicillin-resistant S. pneumoniae is suspected, bacteriological studies should be performed to determine the causative organisms and their susceptibility when AUGMENTIN XR is prescribed.

Acute bacterial sinusitis or community-acquired pneumonia due to a penicillin-susceptible strain of S. pneumoniae plus a β-lactamase−producing pathogen can be treated with another AUGMENTIN® (amoxicillin/clavulanate potassium) product containing lower daily doses of amoxicillin (i.e., 500 mg every 8 hours or 875 mg every 12 hours). Acute bacterial sinusitis or community-acquired pneumonia due to S. pneumoniae alone can be treated with amoxicillin.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of AUGMENTIN XR and other antibacterial drugs, AUGMENTIN XR should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Purification of rare Hematopoietic Stem Cell(s) (HSC) to homogeneity is required to study their self-renewal, differentiation, phenotype, and homing. Long-term repopulation (LTR) of irradiated hosts and serial transplantation to secondary hosts are the gold standard for demonstrating self renewal and differentiation, the defining properties of HSC. We show that rare cells that home to bone marrow can LTR primary and secondary recipients. During the homing, CD34 and SCA-1 expression increases uniquely on cells that home to marrow. These adult bone marrow cells have tremendous differentiative capacity as the can also differentiate into epithelial cells of the liver, lung, GI tract, and skin. This finding may contribute to clinical treatment of genetic disease or tissue repair.
A 12 week fasting/feeding regiment of 16 hours fasting /8 hours feeding each day is chosen. This ratio has been shown to be tolerable in older individuals.
Participants received age-adjusted total daily oral dose approximately equivalent to the adult dose of 10 milligrams per day (mg/d) of balovaptan (RO5285119). Approximate treatment duration was up to 24 weeks (up to 52 additional weeks for those enrolled in the OLE).
Patients receive systemic therapy. Beginning 1-6 weeks after starting systemic therapy, patients also undergo Y90 radioembolization.
LASIK has become one of the most common refractive eye procedures performed in the country. In the mixed astigmatism procedure, a combination of both a steepening (hyperopic treatment) and a flattening (myopic treatment) occur on the corneal surface. The surgeon will produce a standard keratomileusis flap using a microkeratome, exposing the corneal stroma. Recontouring under the flap is then accomplished by the removal of tissue from the stroma with the laser. This recontouring results in an altering of effective lens power of the central cornea, measured in diopters (D). The MEL 80 Excimer Laser System will be evaluated for its ability to create accurate and stable mixed astigmatic refractive correction results.
Approximately 10,000 children in France with growth hormone deficiency (GHD) are being administered daily recombinant human growth hormone (rhGH). Although this treatment has long proved efficient for restoring children's growth and metabolism, daily injections of rhGH have a few limitations, such as difficulties in terms of adherence to treatment, which may compromise growth during childhood but also metabolism in adulthood. In addition to the disease burden and besides the adherence hurdles, the obligations related to daily injection have a negative impact on the quality of life of patients and their families. The hypothesis that injections administered at intervals of 1 week, or even 1 month, could improve compliance, reduce treatment discontinuations, and optimize quality of life and therapeutic effectiveness has led to the emergence of new long-acting growth hormone (LAGH). Recent access to LAGHs (somatrogon MA) on the European and French market will likely be followed by a high demand from the families concerned and may raise questions on their effectiveness, safety, and practical use. Numerous practical and practice-related points are needed to guide prescribing physicians while many concerns are still left unresolved (treatment effectiveness or ineffectiveness endpoints, long-term effectiveness, etc.). These issues can only be addressed in the future by compiling registries and conducting long-term real-world studies.
Hyaluronic acid is used to prepare a medicament for injection into female prostatic tissue for the treatment of female sexual or urinary dysfunction. Independent claims are also included for: (1) a composition comprising hyaluronic acid and an androgen; (2) a kit for treating female sexual or urinary dysfunction, comprising hyaluronic acid (45-75 mg) and an androgen (1-5 mg) and means for administering them simultaneously, separately or sequentially and instructions for administering them. ACTIVITY : Uropathic; Gynecological. A woman with sexual problems (reduced libido, difficulty in achieving orgasm) was treated by injecting the composition of the invention (unspecified) into the G spot. The resultant swelling of the G spot reestablished orgasms and improved sexual satisfaction. MECHANISM OF ACTION : None given.
The present invention is directed to an isolated delta-6 desaturase gene from Schizochytrium. It is further directed to the cloning of delta-6 desaturase derived from Schizochytrium in Yeast. The nucleic acid sequence and the amino acid sequences of the delta-6 desaturase are disclosed. Further disclosed are the constructs, vector comprising the gene encoding the enzyme delta-6 desaturase in functional combination with the heterologous regulatory sequences. The novel delta-6 desaturase can be used in a metabolic pathway to convert linoleic acid to gamma linolenic acid (omega-6 pathway). The invention provides the identification, isolation of these novel nucleic acids from Schizochytrium that encode the above-mentioned proteins.; The invention specifically exemplifies recombinant yeast cells harboring the vector comprising the delta-6 desaturase gene and by the virtue of the enzyme produced shall be able to produce gamnia-linolenic acid.
Serotonin syndrome, a potentially life-threatening reaction, may occur when amphetamines are used in combination with other drugs that affect the serotonergic neurotransmitter systems such as monoamine oxidase inhibitors (MAOIs), selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John’s Wort (see DRUG INTERACTIONS). The coadministration with cytochrome P450 (CYP2D6) inhibitors increase the risk with increased exposure to Mixed Salts of a Single Entity Amphetamine Product. In these situations, consider an alternative non-serotonergic drug or an alternative drug that does not inhibit CYP2D6 (see DRUG INTERACTIONS).

Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea).

Concomitant use of Mixed Salts of a Single Entity Amphetamine Product with MAOI drugs is contraindicated (see CONTRAINDICATIONS).

Discontinue treatment with Mixed Salts of a Single Entity Amphetamine Product and any concomitant serotonergic agents immediately if the above symptoms occur, and initiate supportive symptomatic treatment. If concomitant use of Mixed Salts of a Single Entity Amphetamine Product with other serotonergic drugs or CYP2D6 inhibitors is clinically warranted, initiate Mixed Salts of a Single Entity Amphetamine Product with lower doses, monitor patients for the emergence of serotonin syndrome during drug initiation or titration, and inform patients of the increased risk for serotonin syndrome.
PROBLEM TO BE SOLVED: To improve the stability of a drug in a liquid formulation by adding an oppositely charged ionic substance having a high dehydrating energy of the molecule at a high concentration to the water-soluble charged drugs unstable in an aqueous solution. SOLUTION: (B) A water-soluble oppositely charged ionic substance having >=3,000 cal/mol.A2 dehydrating energy of the molecule (preferably an inorganic or an organic electrolyte, e.g. a nitrate) in an amount of >=100 M is formulated with (A) 1 M of a water-soluble charged drug unstable in an aqueous solution (e.g. a vitamin B1 derivative, tryptophan or a peptidic drug) to thereby improve the stability of the liquid formulation. Furthermore, (C) a water-soluble amphoteric substance having >=800 cal/mol.A2 dehydrating energy (preferably an amino acid) in an amount of >=1,300 M based on 1 M of the ingredient A is formulated therewith to thereby improve the stability of the liquid formulation. The water- solubility of the ingredients A to C is preferably <=1 logP.